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Introduction: The morbidity associated with ablative condition-
ing has prevented the widespread application of bone marrow (BM)
transplantation (BMT) to treat autoimmune diseases and hemo-
globinopathies. To reduce the risk-beneﬁt ratio of establishing
chimerism, less-toxic approaches for conditioning recipients have
been pursued. As one approaches the threshold for conditioning,
failure of durable chimerism occurs with an increasing frequency.
In the present studies, we evaluated the effect of non-ablative
conditioning regimens on sensitization after graft failure and BM
re-transplantation. Materials and Methods: Recipients were in-
fused with MHC-disparate BMC in the context of costimulatory
molecule blockade. In the primary BMT, B6 (H-2b) mice were
treated with anti-
-TCR mAb (day-3) and/or anti-CD154 (day0
and day3), but without any total body irradiation (TBI), then
transplanted with 15  106 allogeneic BALB/c (H-2d) BM cells.
Secondary BMT was performed 5-7 weeks after primary BMT
with 950 cGy TBI and 15  106 BALB/c BM cells. Results: As
expected, engraftment did not occur in mice after primary BMT.
All animals survived. After secondary BMT with 950 cGy TBI
conditioning, engraftment occurred in 25% of mice treated with
anti-
TCR alone at primary BMT. In contrast, all mice engrafted
after secondary BMT with initial treatment of anti-
TCR plus
anti-CD154, and 75% of mice engrafted with anti-CD154 treat-
ment alone at the ﬁrst BMT. Flow cytometry cross-match assay
was performed to detect anti-donor Abs in the sera collected 4
weeks after the ﬁrst BMT. The values are reported as mean
ﬂuorescence intensity (MFI). The Ab titers were 4.92.6 MFI in
mice treated with anti-CD154 and 4.00.4 in mice treated with
both anti-
TCR and anti-CD154 resembled the Ab level in naı¨ve
mice (3.40.5). Ab titers were signiﬁcantly higher in mice treated
with anti-
TCR mAb alone (47.771.3; P0.05) and the non-
mAb treated group (12334.7).Conclusion:These results suggest
that CD154:CD40 co-stimulatory blockade used at the time of
primary BMT promotes allogeneic engraftment in secondary
BMT after engraftment failure. The mechanism is that anti-
CD154 inhibits B cell activation and generation of alloantibody
after primary BMT. Circulating anti-donor Abs are therefore the
critical hurdle for the success of secondary BMT. These ﬁndings
could have a signiﬁcant impact on management of clinic recipients
who have failed at primary BMT and require retransplantation.
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THE IMPACT OF EARLY ONSET OF HEMOPHAGOCYTOSIS AFTER
TRANSPLANTATION ON THE OUTCOME OF ALLOGENIC STEM CELL
TRANSPLANTATION
Yasuda, T.1, Ito, M.1, Imahashi, N.1, Nisiwaki, S.1, Yanagisawa, M.1,
Takahashi, T.1, Kuwatuka, Y.1, Oba, T.1, Miyamura, K.1, Kodera, Y.1
1Nagoya First Red Cross Hospital, Nagoya, Aichi, Japan.
[Introduction] Recently, the concept of early onset of hemoph-
agocytosis after transplantation has been proposed, but the inci-
dence, pathological ﬁndings and prognosis have not clariﬁed. We
analyzed how the early onset of hemophagocytosis after transplan-
tation affects the outocome of allogenic stem cell transplantation.
[Patients and methods] Fifty-two patients received their trans-
plants at the Nagoya First Red Cross Hospital from May 2005 to
April 2006. Forty-ﬁve patients of the 52 patients received marrow
aspiration in early stage of transplantation (until day30), and were
included in the current study. Patients’ ages were from 17 to 65
(median 42) years old. Forty patients were malignant diseases, and
5 patients were non-malignant diseases. Nineteen patients received
reduced intensity stem cell transplantation (RIST) regimen, and 36
patients received conventional regimen. Thirty-two patients re-
ceived BMT, 8 patients received PBSCT, and 5 patients did CBT.
Clots of bone marrow were retrospectively analyzed by a pathol-
ogist, and they were divided into three groups according to the
intensity of pathological ﬁndings of hemophagocytosis as group A
(no hemophagocytosis), group B (mild hemophagocytosis) , and
group C (severe hemophagocytosis). We compare three groups
with the clinical parameters.
[Results] Twenty-two patients were included in group A (49%),
13 patients in group B (29%), and 10 patients in group C (22%).
The average of maximum T-bilirubin in early stage of transplan-
tation (until day 30) was 1.60 mg/dl (group A), 2.68 mg/dl (group
B), and 6.49 mg/dl (group C).There was signiﬁcant difference
between A group to C group (p0.01). Similarly, the average of
maximum creatinine was 0.78 mg/dl (group A), 0.75 mg/dl (group
B), and 1.26 mg/dl (group C). There was signiﬁcant difference
between A group and B group to C group (p0.01). Disease free
survival until day 100 was 4.5% (group A), 7.7% (group B) and
40% (group C) (p0.02).
[Conclusion] It is supposed that the occurrence of hemophago-
cytosis until day 30 were well associated with elevation of T-
bilirubin and creatinine, and early mortality. To conﬁrm a clinical
signiﬁcance of hemophagocytosis, farther studies are needed.
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ALTERATION OF NK TOLERANCE EARLY POST-ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION RESULTS IN NK ALLOREACTIVITY
DRIVEN BY LACK OF RECIPIENT HLA LIGAND FOR DONOR INHIBITORY
KIR
Yu, J.1, Chewning, J.1, Hsu, K.2 1Sloan-Kettering Institute, New York,
NY; 2Memorial Sloan-Kettering Cancer Center, New York, NY.
Donor NK alloreactivity can play a signiﬁcant role in hema-
topoietic cell transplantation (HCT) outcome by decreasing
leukemia relapse and increasing survival. How NK cells in HCT
behave through killer Ig-like receptor (KIR) recognition of
target cell HLA has been the subject of discussion, with evi-
dence supporting a “missing self HLA” mechanism, relevant to
KIR ligand incompatible (HLA-mismatched) HCT, and other
studies supporting a “missing HLA ligand” mechanism, relevant
to both HLA-matched and mismatched HCT. We propose that
in HCT these two mechanisms need not be mutually exclusive.
Using 6-color ﬂow cytometric analysis of intracellular IFN-
production, we evaluated the response of inhibitory KIR-ex-
pressing NK subsets following activation with 721.221, a target
cell line deﬁcient in class I expression, or with 721.221 trans-
fectants expressing the KIR ligands HLA-Cw3, -Cw4, or -Bw4.
NK cells from 10 KIR haplotype-A homozygous individuals and
from 7 T-cell depleted HCT donor-recipient pairs were evalu-
ated. In normal individuals, mature NK cells expressing inhib-
itory KIR speciﬁc for self-HLA were signiﬁcantly more respon-
sive to target cells lacking KIR ligand than NK cells expressing
inhibitory KIR for non-self HLA (P0.001), consistent with
“missing self” behavior. NK cells expressing KIR2DL3, 2DL1,
and 3DL1 all demonstrated similar response patterns, which
were predictable based on the HLA background of the individ-
ual. However, NK cells from HCT patients displayed signiﬁ-
cantly different response patterns to the same target cells: com-
pared to the NK subsets in the donor, the recipient NK
response to lack of HLA ligand, both self and non-self, was higher
at days 15-60 (P0.001), decreasing to donor levels by day 100.
Indeed, the response of NK cells speciﬁc for non-self HLA early
post-HCT was equivalent to the response of NK cells speciﬁc
for self-HLA in a normal individual. Thus, while the mature
NK cell achieves tolerance by preferentially endowing func-
tional competence to inhibitory KIR speciﬁc for self-HLA
(“missing self”), the stem cell-derived NK cell post-HCT
achieves this self-tolerance only after transitioning from a state
where all inhibitory KIR receptors are capable of recognizing
lack of ligand (“missing ligand”). These results indicate that NK
alloreactivity in HCT is driven by both mechanisms and that
HLA-identical HCT recipients beneﬁt from NK alloreactivity
early post-HCT due to lack of HLA ligand for donor inhibitory
KIR.
GVH/GVL
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HUMAN TREGS INDUCED BY ECDI-COUPLED APC FOR THE SUPPRES-
SION OF TRANSPLANTATION ALLORESPONSES
Albert, M.H.1, Magg, T.1 1Pediatric Hematology/Oncology, Dr. von
Haunersches Kinderspital, Munich, Germany.
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Adoptive transfer of polyclonal CD4CD25 regulatory T cells
(nTregs) can tolerize transplantation alloresponses and prevent
lethal acute graft-versus-host disease (GVHD). However isolation
of human CD4CD25 nTregs for adoptive immunotherapy in
sufﬁcient numbers is cumbersome and prone to contamination
with non-regulatory, alloreactive CD25 T-cells. Incubation of
ethylcarbodiimide (ECDI)-coupled antigen presenting cells (APC)
with naı¨ve T-cells and antigen has been shown to have tolerizing
potential in various experimental models.
We have therefore hypothesized that ECDI-coupled APC would
be able to tolerize alloreactive naı¨ve CD4 T-cells from HLA-
incompatible human donors, and have tested whether this would
induce an alloantigen-speciﬁc, Treg-like CD4 population
(ECDI-Tregs). We further investigated whether these cells could
be expanded ex vivo without loss of their regulatory capacity.
After 5 days of culture, ECDI-Tregs were equally potent as
freshly isolated nTregs to suppress proliferation of effector T-cells
in a mixed lymphocyte reaction with allo-APC from the original
APC donor but not with third party APC. Foxp3 mRNA levels in
ECDI-Tregs were equal to nTregs and up to 10-fold higher than
in freshly isolated CD4 cells. The effector T-cells co-cultured
with ECDI-Tregs secreted markedly reduced levels of IL-4, IL-10,
IFN- and TNF-
, similar to cultures with nTregs. Addition of
IL-2 and rapamycin and weekly re-stimulation with untreated
allo-APC led to exponential expansion of ECDI-Tregs with in-
creasing foxp3 levels and without loss of their suppressive activity
after 28 days.
These ﬁndings provide a proof of principle that ECDI-coupled
allo-APC can induce a potent, alloantigen-speciﬁc regulatory T-
cell population that can be expanded ex vivo. These inducible
Tregs suggests a novel approach to enhance the feasibility and
effectiveness of inducing tolerance by Tregs as an adoptive immu-
notherapy in transplantation.
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RITUXIMAB INFUSION TWO MONTHS AFTER TOTAL LYMPHOID IRRA-
DIATION-ANTITHYMOCYTE GLOBULIN (TLI-ATG) NONMYELOABLA-
TIVE TRANSPLANTATION MAINTAINS B-CELL DISEASE CONTROL WITH
MINIMAL GVHD
Arai, S.1, Sahaf, B.1, Jones, C.1, Zehnder, J.1, Lowsky, R.1, Strober, S.1,
Shizuru, J.1, Negrin, R.1, Johnston, L.1, Laport, G.1, Goldstein, K.1,
Brown, J.1, Elder, L.1, Tierney, K.1, Lavori, P.1, Miklos, D.1 1Stanford
University, Stanford, CA.
B cells are implicated in the pathophysiology of chronic GVHD,
as evidenced by the association of Ab production against minor
histocompatibility Ags and rituximab efﬁcacy in chronic GVHD.
We hypothesize that anti-B cell therapy starting day 56 after
nonmyeloablative TLI-ATG transplantation can diminish donor B
cell immunity and thereby reduce chronic GVHD. We chose
chronic lymphocytic leukemia (CLL) and mantle cell lymphoma
(MCL) for the ability to offset any loss of GVL with rituximab’s
direct anti-B cell tumor efﬁcacy.
Patients were conditioned with TLI (80 cGy in10 fractions,
d-11 to d-1) and ATG (1.5mg/kg/day, d-11 to d-7, total 7.5mg/
kg). PBSC infused day 0. GVHD prophylaxis was MMF and
cyclosporine. Rituximab (375 mg/m2) was infused on days 56,
63, 70, and 77.
Fourteen patients have received HCT and the 4 rituximab
infusions. Median age 58 (range 46-65). All 6 CLL patients were
ﬂudarabine-refractory and had unmutated IgVH. Median fol-
low-up 322 days. No infusional toxicities but transient leuko-
penia was noted post-rituximab. One graft failure occurred at
d136 in a patient with MCL progression. Full donor chimerism
occurred as late as 6-9 months with objective GVL. Peripheral
CD19 B cells were undetectable post-rituximab and are re-
constituting at one year. Infections post-transplant include early
CMV reactivation (5), inﬂuenza B (1), aspergillus sinusitis (2),
ecthyma gangrenosum (1), VZV (1). All infections resolved.
NRM at 100 days is 0%. All 6 CLL patients had measurable
disease with ﬁve achieving molecular remission. One CLL pa-
tient had mixed chimerism with CLL progression and received
DLI 9 months after HCT achieving complete molecular CR,
complete chimerism and no GVHD at 60 days. Four MCL
patients transplanted in CR remain in CR. Among the 4 MCL
patients transplanted in PR, one achieved CR and 3 progressed
before rituximab infusion and subsequently died. No acute
GVHD has occurred. Two patients developed chronic GVHD
that resolved with steroids.
In summary, rituximab infusion 56-77 days after TLI-ATG
HCT is well tolerated and provides safe in vivo peripheral donor B
cell depletion without detrimental effect on engraftment or infec-
tion incidence. No acute GVHD occurred and thus far low chronic
GVHD is observed. Importantly, GVL is maintained in all 6 CLL
patients.
Disease
Median
age
Median
f/u MRD/URD GVHD
CD3>95%
Donor
chimerism
Disease status
pre-HCT3last
f/u
6 CLL 58 years 322
days
11 MRD/3
URD
No aGVHD D56
pre-rituximab:
2/14 pts >95%
MCL:4CR
3CR; 1PR
3CR; 3PR3PD
death
8 MCL Two cGVHD,
D257,D342
D180: 6/10 pts
>95%
CLL: 5PR3CR;
1PR3PD (DLI
@ 7 mos)
One graft
failure D136
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CDR3 SIZE SPECTRATYPE ANALYSIS OF PATIENTS WITH CHRONIC
GRAFT-VERSUS HOST DISEASE REVEALS COMPLEXITY OF THE T CELL
REPERTOIRE
Azhipa, O.Y.1, Rowley, S.D.1, Donato, M.L.1, Korngold, R.1,
Friedman, T.M.1 1The Cancer Center, Hackensack University Medical
Center, Hackensack, NJ.
Chronic graft-versus host disease (cGVHD) in patients receiv-
ing allogeneic hematopoietic stem cell transplantation (HSCT)
is a complicated syndrome with autoimmune-like features and
multiorgan manifestations. There has been a gradual increase in
the incidence of cGVHD along with the expanded use of mo-
bilized peripheral blood as a source of stem cells for transplants.
Efforts are being made to standardize the criteria for diagnosis
and staging of cGVHD, but there is little understanding of
immune perturbations associated with the disease. T cell rep-
ertoire reconstitution after allo-HSCT often takes many
months to several years and is thought to be impaired by many
factors such as conditioning regimens, diminished thymic out-
put and stem cell source. Although the perception is that
cGVHD adversely impacts the complexity and diversity of the
reconstituting repertoire, there are only a few studies that have
speciﬁcally examined the repertoire at a molecular level and the
results are inconsistent. We thus sought to assess the diversity
and complexity of the T cell repertoire of cGVHD patients by
T cell receptor V CDR3-size spectratype analysis. To this end,
a cohort of 9 patients who underwent allo-HSCT was enrolled
in the study. Eight of the 9 patients had a previous history of
acute GVHD with no evidence of infectious disease. Peripheral
blood was collected from each cGVHD patient at one time
point ranging from 4 months to 3 years, and ﬂow cytometric and
V spectratype analysis was performed. Flow cytometric anal-
ysis revealed diverse absolute numbers of CD4 and CD8 T
cells among the patients tested, which were correlated with the
post-transplant period. We determined the recipient TCR-V
complexity index within each resolvable family, which repre-
sented the percentage of the number of peaks found for each
V, relative to that found in the average corresponding V
family of 10 healthy donors. The results indicated that 41-88%
(Avg.70; Median 72%) of the resolved V families in all 9
patients were fully complex, with the lower ranges correspond-
ing to those patients sampled early post-HSCT. V 2, 4, 6, and
12 families revealed the best recovery in all patients. In addition,
all 9 patients exhibited skewing in many TCR V families,
suggesting heterogeneous T cell responses. Despite the pres-
ence of skewed T cell responses in all patients, the overall
repertoire remains complex.
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